External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<p>CIPLA delivered a better-than-expected 3QFY22 performance, led by robust growth in the Domestic Formulation (DF) segment, steadily improving sales in North America (NA), and better operating leverage. This was partly offset by a momentary slowdown in API sales in the developed markets. We raise our FY22E/FY23E/FY24E EPS estimate by 3%/6%/4%, factoring in a) market share gains in already launched ANDAs and upcoming potential new launches, such as Lanreotide, b) strong growth in anchor consumer brands in India/South Africa, and c) moderation in the API business outlook.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

CIPLA delivered a better-than-expected 3QFY22 performance, led by robust growth in the Domestic Formulation (DF) segment, steadily improving sales in North America (NA), and better operating leverage. This was partly offset by a momentary slowdown in API sales in the developed markets. We raise our FY22E/FY23E/FY24E EPS estimate by 3%/6%/4%, factoring in a) market share gains in already launched ANDAs and upcoming potential new launches, such as Lanreotide, b) strong growth in anchor consumer brands in India/South Africa, and c) moderation in the API business outlook.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Superior execution drives India/US performance

Cipla Ltd

Superior execution drives India/US performance